This clinical trial focuses on preventing opioid-induced constipation in patients with advanced cancer. Opioids are strong pain-relieving medications often used by cancer patients, but they can cause constipation, which is a common side effect. The study will compare two treatments: Movicolon Naturel, an oral solution containing macrogol 3350 and electrolytes like sodium hydrogen carbonate, potassium chloride, and sodium chloride, and Magnesiumhydroxide Teva, a chewable tablet containing magnesium hydroxide.
The purpose of the study is to determine if magnesium hydroxide is as effective as macrogol/electrolytes in preventing constipation caused by opioids. Participants will be patients with advanced cancer who are starting opioid treatment for pain management. The study will last for 14 days, during which the effectiveness of the treatments will be assessed based on the absence of constipation.
Throughout the study, participants will be monitored for changes in bowel function, quality of life, and any side effects from the laxatives. The study will also evaluate the cost-effectiveness of the treatments and patient satisfaction. The goal is to find a reliable way to prevent constipation in patients who need opioids for pain relief, improving their overall comfort and quality of life.
The Netherlands 
